Board

Dmitrij is Partner at Forbion where, as a core member of the investment team, he contributes to investments across various stages, treatment modalities and diseases. Previously, he was Senior Director of Global Business Development & Licensing at Bayer Pharma, where he was responsible for ophthalmology, cardiology, nephrology, and pulmonology. Dmitrij currently serves as a board …

Dr. Dmitrij Hristodorov Director Read More »

Sam has over 30 years’ experience in the Life Sciences sector as a scientist, company CEO and investment manager. He is currently Managing Partner at IP Group plc., the FTSE 250 investor, where he oversees the group’s c.£500m Life Sciences portfolio. He is founding CEO and Chairman of Istesso Ltd, a Phase 2 drug-discovery company, …

Dr. Sam Williams Read More »

Kenneth is a Partner at Rosetta Capital, a venture capital firm focussed on the life sciences and medical devices . Ken has over 35 years’ experience in the life sciences sector in a career combining senior operating roles in healthcare companies (Abbott Labs., Serono SA) and life science fund management (SV Health Investors, Paul Capital, …

Dr. Kenneth Macleod, PhD Read More »

Christina is co-founder and Managing Director of V-Bio Ventures. With more than 20 years of investment experience in European venture capital, Christina was previously a partner with Forbion Capital Partners (formerly ABN AMRO Capital) where she led and managed a series of successful biotech investments since 2001. Christina currently serves on the boards of Confo …

Christina Takke, PhD Director Read More »

Rafiq is the CEO of Complement Therapeutics, a life sciences company aiming to develop the next generation of complement medicines. Rafiq has pursued a successful career in the pharmaceutical industry globally, including senior positions in ophthalmology with Bayer and Novartis. Most recently as Senior Vice President and Global Head of Ophthalmology at Bayer, Rafiq grew …

Dr. Rafiq Hasan Director Read More »